Axitinib plus Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma: Biomarker Analysis and Updated Results of the Phase II Trial

Key Points

• This research aims to analyze the efficacy of axitinib plus avelumab in different subtypes of adenoid cystic carcinoma (ACC).
• Conducted a Phase II clinical trial for axitinib and avelumab in patients with ACC subtypes.
• Performed biomarker analysis focusing on a 167-gene immune-related signature.
• Utilized patient stratification based on ACC subtype for treatment outcomes.
• Significant differences in treatment outcomes were observed across ACC subtypes.
• The 167-gene immune-related signature successfully predicted clinical benefit from immunotherapy.
• Findings support potential for developing biomarker-driven trial designs for ACC.

Abstract